5-Fu-Based Doublet Regimen in Patients Receiving Perioperative or Postoperative Chemotherapy for Locally Advanced Gastric Cancer: When to Start and How Long Should the Regimen Last?

References

• Feng R-M, Zong Y-N, Cao S-M, Xu R-H. Current cancer situation in China: good or bad news from the 2018 global cancer statistics? Cancer Commun. 2019;39(1):22. doi:10.1186/s40880-019-0368-6
   PubMed Web of Science ®Google Scholar
• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.2149230207593
   PubMed Web of Science ®Google Scholar
• Sakuramoto S, Sasako M, Yamaguchi T, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Eng J Med. 2007;357(18):1810–1820. doi:10.1056/NEJMoa072252
   PubMed Web of Science ®Google Scholar
• Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001;345(10):725–730. doi:10.1056/NEJMoa01018711547741
   PubMed Web of Science ®Google Scholar
• Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355(1):11–20. doi:10.1056/NEJMoa05553116822992
   PubMed Web of Science ®Google Scholar
• Bang Y-J, Kim Y-W, Yang H-K, et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a Phase 3 open-label, randomised controlled trial. Lancet. 2012;379(9813):315–321. doi:10.1016/S0140-6736(11)61873-422226517
   PubMed Web of Science ®Google Scholar
• Al-Batran S-E, Homann N, Pauligk C, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, Phase 2/3 trial. Lancet. 2019;393(10184):1948–1957. doi:10.1016/S0140-6736(18)32557-130982686
   PubMed Web of Science ®Google Scholar
• Badgwell B, Das P, Ajani J. Treatment of localized gastric and gastroesophageal adenocarcinoma: the role of accurate staging and preoperative therapy. J Hematol Oncol. 2017;10(1):149. doi:10.1186/s13045-017-0517-928810883
   PubMed Web of Science ®Google Scholar
• Xiao H, Zhou H, Zhang P, et al. Association among the prognostic nutritional index, completion of adjuvant chemotherapy, and cancer-specific survival after curative resection of stage II/III gastric cancer. Eur J Clin Nutr. 2020;74(4):555–564. doi:10.1038/s41430-019-0502-131548596
   PubMed Web of Science ®Google Scholar
• Park HS, Jung M, Kim HS, et al. Proper timing of adjuvant chemotherapy affects survival in patients with stage 2 and 3 gastric cancer. Ann Surg Oncol. 2015;22(1):224–231. doi:10.1245/s10434-014-3949-225081339
   PubMed Web of Science ®Google Scholar
• Qu J-L, Qu X-J, Li X, et al. Early initiation of fluorouracil-based adjuvant chemotherapy improves survival in patients with resectable gastric cancer. J BUON. 2015;20(3):800–807.26214633
   PubMed Web of Science ®Google Scholar
• Huang SM, Chen YC, Chen WY, et al. Optimal timing for postsurgical adjuvant therapy in patients with gastric cancer: a propensity score matching study. J Cancer. 2019;10(2):332–340. doi:10.7150/jca.2775330719127
   PubMed Web of Science ®Google Scholar
• Brenkman HJF, van Putten M, Visser E, et al. Timing of postoperative chemotherapy in patients undergoing perioperative chemotherapy and gastrectomy for gastric cancer. Surg Oncol. 2018;27(3):421–427. doi:10.1016/j.suronc.2018.05.02630217297
   PubMed Web of Science ®Google Scholar
• Qu J-L, Li X, Qu X-J, et al. Optimal duration of fluorouracil-based adjuvant chemotherapy for patients with resectable gastric cancer. PLoS One. 2013;8(12):e83196. doi:10.1371/journal.pone.008319624386161
   PubMed Web of Science ®Google Scholar
• Daly MB, Pilarski R, Berry M, et al. NCCN guidelines insights: genetic/familial high-risk assessment: breast and ovarian, version 2.2017. J Natl Compr Canc Netw. 2017;15(1):9–20. doi:10.6004/jnccn.2017.000328040716
   PubMed Web of Science ®Google Scholar
• Li Z, Wang Y, Shan F, et al. ypTNM staging after neoadjuvant chemotherapy in the Chinese gastric cancer population: an evaluation on the prognostic value of the AJCC eighth edition cancer staging system. Gastric Cancer. 2018;21(6):977–987. doi:10.1007/s10120-018-0830-129748876
   PubMed Web of Science ®Google Scholar
• UDo H, Services H. Common terminology criteria for adverse events (CTCAE) version 4.0. Natl Cancer Inst. 2009;4(03).
   Google Scholar
• Harrell JFE. Regression Modeling Strategies: With Applications to Linear Models, Logistic and Ordinal Regression, and Survival Analysis. Springer; 2015.
   Google Scholar
• Noh SH, Park SR, Yang H-K, et al. Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial. Lancet Oncol. 2014;15(12):1389–1396. doi:10.1016/S1470-2045(14)70473-525439693
   PubMed Web of Science ®Google Scholar
• Cirera L, Balil A, Batiste-Alentorn E, et al. Randomized clinical trial of adjuvant mitomycin plus tegafur in patients with resected stageIII gastric cancer. J Clin Oncol. 1999;17(12):3810–3815. doi:10.1200/JCO.1999.17.12.381010577853
   PubMed Web of Science ®Google Scholar
• Lim L, Michael M, Mann GB, Leong T. Adjuvant Therapy in Gastric Cancer. J Clin Oncol. 2005;23(25):6220–6232.16135489
   PubMed Web of Science ®Google Scholar
• Kilic L, Ordu C, Yildiz I, et al. Current adjuvant treatment modalities for gastric cancer: from history to the future. World J Gastrointest Oncol. 2016;8(5):439–449. doi:10.4251/wjgo.v8.i5.43927190583
   PubMed Web of Science ®Google Scholar
• Cai Z, Yin Y, Yin Y, et al. Comparative effectiveness of adjuvant treatments for resected gastric cancer: a network meta-analysis. Gastric Cancer. 2018;21(6):1031–1040. doi:10.1007/s10120-018-0831-029728791
   PubMed Web of Science ®Google Scholar
• Sun J, Ren Z, Sun X, Hou H, Li K, Ge Q. Efficacy and safety comparison of chemotherapies for advanced gastric cancer: a network meta-analysis. Oncotarget. 2017;8(24):39673–39682. doi:10.18632/oncotarget.1778428562333
   PubMedGoogle Scholar
• Wang F-H, Shen L, Li J, et al. The Chinese Society of Clinical Oncology (CSCO): clinical guidelines for the diagnosis and treatment of gastric cancer. Cancer Commun (Lond). 2019;39(1):10. doi:10.1186/s40880-019-0349-930885279
   PubMed Web of Science ®Google Scholar
• Lee K-W, Zang DY, Ryu M-H, et al. Comparison of efficacy and tolerance between combination therapy and monotherapy as first-line chemotherapy in elderly patients with advanced gastric cancer: study protocol for a randomized controlled trial. Contemp Clin Trials Commun. 2017;8:55–61. doi:10.1016/j.conctc.2017.08.00629696197
   PubMed Web of Science ®Google Scholar
• Zhao J-H, Gao P, Song Y-X, et al. Which is better for gastric cancer patients, perioperative or adjuvant chemotherapy: a meta-analysis. BMC Cancer. 2016;16(1):631. doi:10.1186/s12885-016-2667-527519527
   PubMed Web of Science ®Google Scholar
• Lee C-K, Jung M, Kim HS, et al. S-1 based doublet as an adjuvant chemotherapy for curatively resected stage iii gastric cancer: results from the randomized Phase III POST trial. Cancer Res Treat. 2019;51(1).
   Web of Science ®Google Scholar
• Koizumi W, Kim YH, Fujii M, et al. Addition of docetaxel to S-1 without platinum prolongs survival of patients with advanced gastric cancer: a randomized study (START). J Cancer Res Clin Oncol. 2014;140(2):319–328. doi:10.1007/s00432-013-1563-524366758
   PubMed Web of Science ®Google Scholar
• Koizumi W, Narahara H, Hara T, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 2008;9(3):215–221. doi:10.1016/S1470-2045(08)70035-418282805
   PubMed Web of Science ®Google Scholar
• Cates JMM. Modeling continuous prognostic factors in survival analysis: implications for tumor staging and assessing chemotherapy effect in osteosarcoma. Am J Surg Pathol. 2018;42(4):485–491. doi:10.1097/PAS.000000000000099529200101
   PubMed Web of Science ®Google Scholar
• Petrelli F, Zaniboni A, Ghidini A, et al. Timing of adjuvant chemotherapy and survival in colorectal, gastric, and pancreatic cancer. A systematic review and meta-analysis. Cancers. 2019;11(4):550. doi:10.3390/cancers11040550
   PubMed Web of Science ®Google Scholar
• Lu H, Zhao B, Zhang J, et al. Does delayed initiation of adjuvant chemotherapy following the curative resection affect the survival outcome of gastric cancer patients: a systematic review and meta-analysis. Eur J Surg Oncol. 2020;46(6):1103–1110. doi:10.1016/j.ejso.2020.01.01331948838
   PubMed Web of Science ®Google Scholar
• Wang X-Z, Zeng Z-Y, Ye X, Sun J, Zhang Z-M, Kang W-M. Interpretation of the development of neoadjuvant therapy for gastric cancer based on the vicissitudes of the NCCN guidelines. World J Gastrointest Oncol. 2020;12(1):37–53. doi:10.4251/wjgo.v12.i1.3731966912
   PubMed Web of Science ®Google Scholar
• Brenkman HJF, Ruurda JP, Verhoeven RHA, van Hillegersberg R. Safety and feasibility of minimally invasive gastrectomy during the early introduction in the Netherlands: short-term oncological outcomes comparable to open gastrectomy. Gastric Cancer. 2017;20(5):853–860. doi:10.1007/s10120-017-0695-828185027
   PubMed Web of Science ®Google Scholar
• Ychou M, Boige V, Pignon J-P, et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol. 2011;29(13):1715–1721. doi:10.1200/JCO.2010.33.059721444866
   PubMed Web of Science ®Google Scholar
• Zhang W-Y, Zhang W-J, Bai Y, et al. Impact of adjuvant chemotherapy cycles on prognosis of resectable stomach cancer: a retrospective analysis. Asian Pac J Cancer Prev. 2013;14(1):381–386. doi:10.7314/APJCP.2013.14.1.38123534757
   PubMedGoogle Scholar
• Alderson D, Cunningham D, Nankivell M, et al. Neoadjuvant cisplatin and fluorouracil versus epirubicin, cisplatin, and capecitabine followed by resection in patients with oesophageal adenocarcinoma (UK MRC OE05): an open-label, randomised phase 3 trial. Lancet Oncol. 2017;18(9):1249–1260. doi:10.1016/S1470-2045(17)30447-328784312
   PubMed Web of Science ®Google Scholar
• Petrillo A, Pompella L, Tirino G, et al. Perioperative treatment in resectable gastric cancer: current perspectives and future directions. Cancers. 2019;11(3):399. doi:10.3390/cancers11030399
   PubMed Web of Science ®Google Scholar
• Hebbar M, Chibaudel B, André T, et al. FOLFOX4 versus sequential dose-dense FOLFOX7 followed by FOLFIRI in patients with resectable metastatic colorectal cancer (MIROX): a pragmatic approach to chemotherapy timing with perioperative or postoperative chemotherapy from an open-label, randomized phase III trial. Ann Oncol. 2015;26(2):340–347.25403578
   PubMed Web of Science ®Google Scholar
• Prendergast EN, Holzapfel M, Mueller JJ, et al. Three versus six cycles of adjuvant platinum-based chemotherapy in early stage clear cell ovarian carcinoma - A multi-institutional cohort. Gynecol Oncol. 2017;144(2):274–278. doi:10.1016/j.ygyno.2016.12.00427979319
   PubMed Web of Science ®Google Scholar
• Tantoy IY, Cooper BA, Dhruva A, et al. Quality of life of patients with gastrointestinal cancers undergoing chemotherapy. Qual Life Res. 2018;27(7):1865–1876. doi:10.1007/s11136-018-1860-129679368
   PubMed Web of Science ®Google Scholar
• Lam SW, Wai M, Lau JE, McNamara M, Earl M, Udeh B. Cost-effectiveness analysis of second-line chemotherapy agents for advanced gastric cancer. Pharmacotherapy. 2017;37(1):94–103. doi:10.1002/phar.187027870079
   PubMed Web of Science ®Google Scholar
• Chikhladze S, Lederer A-K, Kousoulas L, et al. Adjuvant chemotherapy after surgery for pancreatic ductal adenocarcinoma: retrospective real-life data. World J Surg Oncol. 2019;17(1):185. doi:10.1186/s12957-019-1732-331706323
   PubMed Web of Science ®Google Scholar
• Coimbra FJF, de Jesus VHF, Ribeiro HSC, et al. Impact of ypT, ypN, and adjuvant therapy on survival in gastric cancer patients treated with perioperative chemotherapy and radical surgery. Ann Surg Oncol. 2019;26(11):3618–3626. doi:10.1245/s10434-019-07454-031222685
   PubMed Web of Science ®Google Scholar
• Jiang D, Wang H, Song Q, et al. Comparison of the prognostic difference between ypTNM and equivalent pTNM stages in esophageal squamous cell carcinoma based on the 8th edition of AJCC classification. J Cancer. 2020;11(7):1808–1815. doi:10.7150/jca.3456732194792
   PubMed Web of Science ®Google Scholar
• Ji J, Shen L, Li Z, et al. Perioperative chemotherapy of oxaliplatin combined with S-1 (SOX) versus postoperative chemotherapy of SOX or oxaliplatin with capecitabine (XELOX) in locally advanced gastric adenocarcinoma with D2 gastrectomy: a randomized phase III trial (RESOLVE trial). Ann Oncol. 2019;30:v877.
   PubMed Web of Science ®Google Scholar
• Li Z, Shan F, Ying X, et al. Assessment of laparoscopic distal gastrectomy after neoadjuvant chemotherapy for locally advanced gastric cancer: a randomized clinical trial. JAMA Surg. 2019;154(12):1093–1101. doi:10.1001/jamasurg.2019.347331553463
   PubMed Web of Science ®Google Scholar